Skip to main content
TipRanks
Go Ultimate75% OFF

Tecan Group AG (TECN) Q2 2026 Earnings Report

7 Followers

CH:TECN Q2 2026 EPS Results

Actual EPS
CHF 2.62
Consensus EPS
CHF 2.51
Beat/Miss
Beat by +CHF 0.11
One Year Ago EPS
CHF 2.64

CH:TECN Q2 2026 Revenue Results

Actual Revenue
CHF 427.52M
Expected Revenue
CHF 428.24M
Beat/Miss
Missed by -CHF 715.00K
YoY Revenue Growth
-2.72%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/11/2026
Time
Before Open
Conference Call
Tuesday, August 11, 2026
CH:TECN Upcoming Earnings

Tecan Group AG's next earnings date is estimated for March 16, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

CH:TECN Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 11, 2026|% Change Since:26.53%|
Earnings Call Sentiment|Positive

The call painted an overall constructive picture: Tecan delivered above-market sales growth in local currencies, maintained a healthy book-to-bill and recorded a resilient adjusted EBITDA margin with underlying profitability improvement. Management confirmed multi-year targets and reported early, tangible benefits from the Rewired transformation alongside strategic AI and geographic initiatives. However, material challenges remain — gross margin compression (material inflation, FX and tariffs), weaker operating cash flow, supply-chain shipment delays (Cavro), upfront transformation and IT costs, and weakness in the Academia & Government end market. On balance, the positive operational momentum, validated guidance and strategic progress outweigh the near-term financial and operational headwinds, but the company must execute Rewired and Elevate while stabilizing cash conversion and margins.

Company Guidance

Tecan reiterated full‑year 2026 guidance for low‑single‑digit sales growth in local currencies (with the aim to grow above the market) and an adjusted EBITDA margin of 15.5–16.5%, saying it currently expects to close the year toward the upper end of that range; management also said the tariff headwind is now expected at roughly 40 basis points for the full year (H1 was ~‑50bps, H2 ~‑30bps) and that a tariff refund of ~CHF 6m is expected in H2. The Rewired program is expected to require CHF 45–60m of OpEx over three years (CHF 7.6m booked in H1) and to help deliver >4% CAGR versus the 2025 baseline to reach the 2028 targets of CHF 1.0bn sales and a 20% adjusted EBITDA margin (and beyond 2028 a mid‑ to high‑single‑digit sales CAGR and >20% margin); Elevate (ERP/CRM) non‑recurring costs were CHF 9.9m in H1 with go‑lives planned in H1 2027.

  • Above-Market Sales GrowthGroup sales of CHF 427.5 million, up 3.4% in local currencies (reported -2.7% due to FX). Q2 sales growth sustained at +3.4% in local currencies.
  • Healthy Order Intake and Book-to-BillOrder entry CHF 444.3 million, up 3.0% in local currencies. Book-to-bill ratio 1.04, above 1 in both Life Sciences and Partnering; Q2 orders stable year-on-year and exceeded Q1 levels.
  • Solid Adjusted EBITDA and Underlying ProfitabilityAdjusted EBITDA CHF 64.6 million with a margin of 15.1% (slightly ahead of the prior year). Adjusted EBITDA was only CHF 1.1 million below prior year and underlying profitability improved by c.108 basis points.
  • Broad-Based Segment GrowthLife Sciences sales +3.1% in local currencies (outperforming lab automation market); Partnering sales +3.6% in local currencies. Biopharma grew high single digits, Diagnostics mid-single digits, MedTech mid-single digits.
  • Regional and Product DriversAsia was the main growth driver with Japan very strong and China mid-single-digit growth; U.S. ~1% growth and Europe stable. Growth supported by liquid-handling instruments and Labwerx customized solutions.
  • Rewired Transformation Showing Early BenefitsRewired launched as a 3-year program to drive >4% CAGR to 2028. H1 Rewired costs booked CHF 7.6 million; first savings are materializing and management expects meaningful contributions to 2027–2028 performance.
  • Strategic Operational Progress and PartnershipsOperational moves include closure of Boston design site, planned exits of selected Genomics activities, divestment of a precision machining site and consolidation in Vietnam, U.S. pipette-tip production operational. Strategic AI partnership with NVIDIA (Agentic AI for Introspect) and expansion into India.
  • Confirmed Guidance and 2028 TargetsCompany reiterates full-year 2026 sales growth expectation of low single digits in local currencies and adjusted EBITDA margin guidance of 15.5%–16.5% (management expects to close toward the upper end). 2028 targets reaffirmed: CHF 1 billion sales and 20% adjusted EBITDA margin.

CH:TECN Earnings History

CH:TECN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 16, 20272026 (Q4)3.83-4.26――
Aug 11, 20262026 (Q2)2.512.622.64-0.76% (-0.02)
Mar 16, 20262025 (Q4)3.394.265.23-18.55% (-0.97)
Aug 12, 20252025 (Q2)2.512.642.86-7.69% (-0.22)
Mar 12, 20252024 (Q4)3.665.236.17-15.24% (-0.94)
Aug 13, 20242024 (Q2)4.452.865.16-44.57% (-2.30)
Mar 12, 20242023 (Q4)5.776.174.3641.51% (+1.81)
Aug 15, 20232023 (Q2)5.585.165.150.19% (+0.01)
Mar 14, 20232022 (Q4)―4.363.0841.37% (+1.28)
Aug 17, 20222022 (Q2)4.515.156.85-24.82% (-1.70)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed